Compare Stocks → Never use this word on your phone (FBI could be watching) (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CNSPNASDAQ:CYCCNASDAQ:CYTONASDAQ:DRMA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNSPCNS Pharmaceuticals$0.22+4.7%$0.30$0.19▼$2.98$2.35M2.78343,521 shs84,084 shsCYCCCyclacel Pharmaceuticals$2.00-19.7%$2.19$1.30▼$13.20$2.64M0.54663,870 shs562,862 shsCYTOAltamira Therapeutics$1.64+1.2%$1.83$1.35▼$28.40$2.59M1.82921,672 shs29,769 shsDRMADermata Therapeutics$0.34$0.39$0.23▼$3.68$2.24M0.89647,375 shs20,489 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNSPCNS Pharmaceuticals+2.59%+1.42%-24.41%-11.56%-88.48%CYCCCyclacel Pharmaceuticals-19.68%+33.33%-9.09%-10.31%-75.76%CYTOAltamira Therapeutics+1.23%-2.96%-15.46%-7.87%-90.41%DRMADermata Therapeutics-1.21%-1.96%-16.63%-25.38%-80.35%Gold Mania (Ad)Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNSPCNS PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACYCCCyclacel Pharmaceuticals1.6762 of 5 stars3.33.00.00.02.90.00.6CYTOAltamira Therapeutics0.4734 of 5 stars0.05.00.00.00.00.81.3DRMADermata TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNSPCNS PharmaceuticalsN/AN/AN/AN/ACYCCCyclacel Pharmaceuticals2.50Moderate Buy$11.00450.00% UpsideCYTOAltamira TherapeuticsN/AN/AN/AN/ADRMADermata TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest CYCC, DRMA, CNSP, and CYTO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/3/2024CYCCCyclacel PharmaceuticalsRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $11.00(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNSPCNS PharmaceuticalsN/AN/AN/AN/A($0.71) per shareN/ACYCCCyclacel Pharmaceuticals$420K6.28N/AN/A$0.57 per share3.51CYTOAltamira Therapeutics$320K8.10N/AN/A$4.56 per share0.36DRMADermata TherapeuticsN/AN/AN/AN/A$1.62 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNSPCNS Pharmaceuticals-$18.85M-$5.66N/A∞N/AN/A-603.40%-421.35%5/20/2024 (Estimated)CYCCCyclacel Pharmaceuticals-$22.56M-$27.22N/AN/AN/AN/A-448.19%-151.29%5/9/2024 (Estimated)CYTOAltamira Therapeutics-$4.31MN/A0.00N/AN/AN/AN/AN/A7/10/2024 (Estimated)DRMADermata Therapeutics-$7.80M-$3.65N/A∞N/AN/A-107.95%-93.59%5/9/2024 (Estimated)Latest CYCC, DRMA, CNSP, and CYTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023CNSPCNS PharmaceuticalsN/A-$0.95-$0.95-$0.95N/AN/A3/21/2024Q4 2023DRMADermata TherapeuticsN/A-$0.21-$0.21-$0.21N/AN/A3/19/2024Q4 2023CYCCCyclacel Pharmaceuticals-$6.35-$6.23+$0.12-$6.23N/A$0.03 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNSPCNS PharmaceuticalsN/AN/AN/AN/AN/ACYCCCyclacel PharmaceuticalsN/AN/AN/AN/AN/ACYTOAltamira TherapeuticsN/AN/AN/AN/AN/ADRMADermata TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNSPCNS PharmaceuticalsN/A0.260.26CYCCCyclacel PharmaceuticalsN/A0.910.91CYTOAltamira TherapeuticsN/A1.381.38DRMADermata TherapeuticsN/A4.914.91OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNSPCNS Pharmaceuticals14.02%CYCCCyclacel Pharmaceuticals23.58%CYTOAltamira Therapeutics1.91%DRMADermata Therapeutics8.67%Insider OwnershipCompanyInsider OwnershipCNSPCNS Pharmaceuticals9.20%CYCCCyclacel Pharmaceuticals8.47%CYTOAltamira Therapeutics13.03%DRMADermata Therapeutics9.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCNSPCNS Pharmaceuticals310.64 million9.66 millionNot OptionableCYCCCyclacel Pharmaceuticals2,0181.32 million1.21 millionOptionableCYTOAltamira Therapeutics101.58 million1.37 millionNot OptionableDRMADermata Therapeutics86.66 million6.04 millionNot OptionableCYCC, DRMA, CNSP, and CYTO HeadlinesSourceHeadlineDermata Therapeutics (NASDAQ:DRMA) Shares Up 1.7%americanbankingnews.com - May 2 at 3:24 AMDermata to Present at the Emerging Growth Conference on April 3, 2024accesswire.com - March 27 at 4:05 PMDermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Resultsaccesswire.com - March 21 at 4:05 PMDermata Therapeutics, Inc. (DRMAW)ca.finance.yahoo.com - February 11 at 3:44 PMPresenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Nowfinance.yahoo.com - February 6 at 7:49 AMDermata Therapeutics Inc DRMAmorningstar.com - February 4 at 12:48 PMDermata to Present at the Emerging Growth Conference on February 7, 2024finance.yahoo.com - February 1 at 10:31 AMDermata stock soars on patent issuance, partnership talksmsn.com - January 7 at 2:38 AMDow Turns Lower; ISM Services PMI Falls In Decembermsn.com - January 5 at 5:22 PMWhy Is Aesthetic Skin Conditions-Focused Dermata Therapeutics Stock Trading Higher Today?msn.com - January 5 at 12:22 PMWhy Is Dermata Therapeutics (DRMA) Stock Up 62% Today?investorplace.com - January 5 at 9:12 AMStocks to Watch: Dermata Therapeutics, Applied Therapeutics, Fusion Pharmaceuticalsmarketwatch.com - January 4 at 9:20 PMDermata Therapeutics Shares Surge 120% on Patent Issued in Japanmarketwatch.com - January 4 at 9:20 PMWhy Dermata Therapeutics Stock Took Off After-Hoursmsn.com - January 4 at 9:20 PMDermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosisfinance.yahoo.com - January 4 at 4:20 PMDermata Therapeutics: Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acnefinanznachrichten.de - December 21 at 1:59 PMDermata Therapeutics Stock (NASDAQ:DRMA) Dividends: History, Yield and Datesbenzinga.com - December 20 at 8:31 PMDermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acnefinance.yahoo.com - December 20 at 8:31 PMDermata Therapeutics Inc.thestreet.com - December 13 at 2:42 AMDermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rulesfinance.yahoo.com - November 16 at 1:39 PMDermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocolsfinance.yahoo.com - November 16 at 8:39 AMDermata Therapeutics GAAP EPS of -$0.54msn.com - November 10 at 10:22 AMDermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 9 at 5:47 PMDermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trialfinance.yahoo.com - October 26 at 1:47 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCNS PharmaceuticalsNASDAQ:CNSPCNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Cyclacel PharmaceuticalsNASDAQ:CYCCCyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Altamira TherapeuticsNASDAQ:CYTOAltamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.Dermata TherapeuticsNASDAQ:DRMADermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.